Viewing data from:

CLOMIPHENE CITRATE

ANDA

CLOMIPHENE CITRATE | A220673 | ASCENT PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

API Supply Chain5 active DMFs4 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVCLOMIPHENE CITRATE

DMF 39571980

FIS FABBRICA ITALIANA SINTETICI SPACLOMIPHENE CITRATE

DMF 56741984

MENADIONA SLCLOMIPHENE CITRATE

DMF 75901988

PCASCLOMIPHENE CITRATE

DMF 289472015

VIYASH LIFE SCIENCES PRIVATE LTDCLOMIPHENE CITRATE USP

DMF 401112024

UNICHEM LABORATORIES LTDInactiveCLOMIPHENE CITRATE

DMF 63361985

EGIS PHARMACEUTICALS PRIVATE LTDInactiveCLOMIPHENE CITRATE USP

DMF 65681986

EGIS PHARMACEUTICALS PRIVATE LTDInactiveCLOMIPHENE CITRATE TABLETS

DMF 86721989

PCASInactiveCLOMIPHENE CITRATE

DMF 147282000

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 50MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: May 15, 2026

No patent or exclusivity listings for this strength.

Change History (1)

Recent changes detected for this application.

ADDED7/1/2026

Ascent Pharms Inc received FDA approval for clomiphene citrate (NDA 220673, Supplement 001).

New: New record